# Study of Omalizumab in Moderate to Severe Bronchial Asthma

> **NCT00232050** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 327 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT00232050
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2011-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00232050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00232050, "Study of Omalizumab in Moderate to Severe Bronchial Asthma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00232050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*